Evidence map›Paper›PMID 30887112›Full record

ArticleJournal of molecular medicine (Berlin, Germany)2019

Activation of NF-κB in B cell receptor signaling through Bruton's tyrosine kinase-dependent phosphorylation of IκB-α.

Marilena Pontoriero, Giuseppe Fiume, Eleonora Vecchio, Annamaria de Laurentiis, Francesco Albano, Enrico Iaccino, Selena Mimmi, Antonio Pisano, Valter Agosti, Emilia Giovannone and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular medicine (Berlin, Germany), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 54 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. NF-kB and the CLL microenvironment.Frontiers in oncology · 2023
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Marilena PontorieroDepartment of Clinical and Experimental Medicine, University of Catanzaro "Magna Græcia", Viale Europa, Germaneto, 88100, Catanzaro, Italy.
Giuseppe FiumeDepartment of Clinical and Experimental Medicine, University of Catanzaro "Magna Græcia", Viale Europa, Germaneto, 88100, Catanzaro, Italy. fiume@unicz.it.ORCID 0000-0002-5414-6190
Eleonora VecchioDepartment of Clinical and Experimental Medicine, University of Catanzaro "Magna Græcia", Viale Europa, Germaneto, 88100, Catanzaro, Italy.
Annamaria de LaurentiisDepartment of Clinical and Experimental Medicine, University of Catanzaro "Magna Græcia", Viale Europa, Germaneto, 88100, Catanzaro, Italy.
Francesco AlbanoDepartment of Clinical and Experimental Medicine, University of Catanzaro "Magna Græcia", Viale Europa, Germaneto, 88100, Catanzaro, Italy.
Enrico IaccinoDepartment of Clinical and Experimental Medicine, University of Catanzaro "Magna Græcia", Viale Europa, Germaneto, 88100, Catanzaro, Italy.
Selena MimmiDepartment of Clinical and Experimental Medicine, University of Catanzaro "Magna Græcia", Viale Europa, Germaneto, 88100, Catanzaro, Italy.
Antonio PisanoDepartment of Clinical and Experimental Medicine, University of Catanzaro "Magna Græcia", Viale Europa, Germaneto, 88100, Catanzaro, Italy.
Valter AgostiDepartment of Clinical and Experimental Medicine, University of Catanzaro "Magna Græcia", Viale Europa, Germaneto, 88100, Catanzaro, Italy.
Emilia GiovannoneDepartment of Clinical and Experimental Medicine, University of Catanzaro "Magna Græcia", Viale Europa, Germaneto, 88100, Catanzaro, Italy.
Annalisa AltobelliDepartment of Molecular Medicine and Medical Biotechnology, University of Naples "Federico II", Via S. Pansini, 80131, Naples, Italy.
Carmen CaiazzaDepartment of Molecular Medicine and Medical Biotechnology, University of Naples "Federico II", Via S. Pansini, 80131, Naples, Italy.
Massimo MallardoDepartment of Molecular Medicine and Medical Biotechnology, University of Naples "Federico II", Via S. Pansini, 80131, Naples, Italy.
Giuseppe ScalaDepartment of Clinical and Experimental Medicine, University of Catanzaro "Magna Græcia", Viale Europa, Germaneto, 88100, Catanzaro, Italy.
Ileana QuintoDepartment of Clinical and Experimental Medicine, University of Catanzaro "Magna Græcia", Viale Europa, Germaneto, 88100, Catanzaro, Italy. quinto@unicz.it.
Magna Graecia University · ITUniversity of Naples Federico II · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The antigen-mediated triggering of B cell receptor (BCR) activates the transcription factor NF-κB that regulates the expression of genes involved in B cell differentiation, proliferation, and survival. The tyrosine kinase Btk is essentially required for the activation of NF-κB in BCR signaling through the canonical pathway of IKK-dependent phosphorylation and proteasomal degradation of IκB-α, the main repressor of NF-κB. Here, we provide the evidence of an additional mechanism of NF-κB activation in BCR signaling that is Btk-dependent and IKK-independent. In DeFew B lymphoma cells, the anti-IgM stimulation of BCR activated Btk and NF-κB p50/p65 within 0.5 min in absence of IKK activation and IκB-α degradation. IKK silencing did not affect the rapid activation of NF-κB. Within this short time, Btk associated and phosphorylated IκB-α at Y289 and Y305, and, concomitantly, p65 translocated from cytosol to nucleus. The mutant IκB-α Y289/305A inhibited the NF-κB activation after BCR triggering, suggesting that the phosphorylation of IκB-α at tyrosines 289 and 305 was required for NF-κB activation. In primary chronic lymphocytic leukemia cells, Btk was constitutively active and associated with IκB-α, which correlated with Y305-phosphorylation of IκB-α and increased NF-κB activity compared with healthy B cells. Altogether, these results describe a novel mechanism of NF-κB activation in BCR signaling that could be relevant for Btk-targeted therapy in B-lymphoproliferative disorders. KEY MESSAGES: Anti-IgM stimulation of BCR activates NF-κB p50/p65 within 30 s by a Btk-dependent and IKK-independent mechanism. Btk associates and phosphorylates IκB-α at Y289 and Y305, promoting NF-κB activation. In primary CLLs, the binding of Btk to IκB-α correlates with tyrosine phosphorylation of IκB-α and increased NF-κB activity.

Indexed as

Agammaglobulinaemia Tyrosine KinaseCell Line, TumorHEK293 CellsHumansLeukemia, Lymphocytic, Chronic, B-CellNF-kappa BNF-KappaB Inhibitor alphaPhosphorylationReceptors, Antigen, B-CellSignal TransductionAgammaglobulinaemia Tyrosine KinaseBTK protein, humanNF-kappa BNF-KappaB Inhibitor alphaReceptors, Antigen, B-CellB-cell receptorBTKIκB-α tyrosine phosphorylationNF-κB

Identifiers

PMID30887112
OpenAlexW2923806832

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.